Effect of Intra-Coronary Nicorandil Administration Prior to Reperfusion in Acute ST Segment Elevation Myocardial Infarction

Relationship between Retrograde Coronary Blood Flow and the Extent of No-Reflow and Infarct Size in a Porcine Ischemia–Reperfusion Model

“…The use of CBF pattern is limited by its application to the left coronary artery only, since the right coronary artery flow pattern follows that of the aorta, peaking during systole [25,26]. However, it is for patients with large infarcts in the territories perfused by the LAD that this additional prognostic information is likely to be important, since it may contribute to the identification of patients needing an aggressive approach, including interventions to reduce the NR phenomenon [27,28].…”

Pharmacological preconditioning. Focus on nicorandil

“…В другом проспективном, рандомизированном исследовании Lee, et al было продемонстрировано, что у пациентов с ИМпST, получавших 2 мг нико-рандила интракоронарно перед КАГ и 2 мг перед установкой стента, без в/в введения, в 4 раза реже наступала комбинированная конечная точка по сравнению с группой контроля: постреперфузи-онная аритмия и феномен no-reflow/slow reflow (p=0,037), улучшался кровоток по шкале TIMI и клинические исходы [41]. В 2007г исследователи Kasama, et al оценивали необходимость продолжения терапии никорандилом после ЧКВ.…”

All-cause mortality and cardiovascular events with nicorandil in patients with IHD: Systematic review and meta-analysis of the literature

“…All of these studies were published in English (13 literatures) [4,[17][18][19][20][21][22][23][24][25][26][27][28] or Chinese (4 literatures) [29][30][31][32]. They were published from 1999 to 2012 and varied in sample size.…”

“…The proportion of males ranged from 52.6% to 85.2%. Fourteen studies reported all-cause mortality by using counting as the outcome [4,[17][18][19][20][21]23,24,26,[28][29][30][31][32]. Eleven studies evaluated cardiovascular events by using counting as the outcome.…”